Law360, New York (June 16, 2009) -- Bristol-Myers Squibb Co. has reached the outline of a settlement in a securities class action that accuses the drugmaker of duping shareholders and causing a stock drop when it failed to properly disclose a patent deal for a generic version of its blood-thinning drug Plavix.
In an endorsed letter dated June 3 but entered into the docket Monday, an attorney for the plaintiffs, Salvatore Graziano of Bernstein Litowitz Berger & Grossman LLP, said that the...
